Xenon Pharmaceuticals Inc. (NASDAQ:XENE) saw an upside of 0.98% to close Tuesday at $31.96 after adding $0.31 on the day. The 5-day average trading volume is 4,290,460 shares of the company’s common stock. It has gained $33.72 in the past week. An average of 5,745,445 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,406,746.
XENE’s 1-month performance is 80.56% or $14.51 on its low of $14.65 reached on 09/27/21. The company’s shares have touched a 52-week low of $9.32 and high of $33.72, with the stock’s rally to the 52-week high happening on 10/08/21. YTD, XENE has achieved 107.80% or $16.58. However, the current price is down -5.22%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On May 28, 138 days have gone by since the last insider trading activity for Xenon Pharmaceuticals Inc. (XENE). ROBIN SHERRINGTON (EVP, Strategy & Innovation) most recently sold 6,067 shares at $18.81 per share on May 28. This transaction cost the insider $114,120. Director, HOLLER FRANK A, sold 11,064 shares at a price of $18.68 on May 27.
Xenon Pharmaceuticals Inc. (XENE) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.19 for the sector.XENE stock has a beta of 1.47. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 85.21 while the price-to-book (PB) in the most recent quarter is 5.53.
Xenon Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 17.80, with the current ratio over the same period at 17.80 meaning that XENE stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00The trailing 12-month EBITDA margin is -95.31%. The firm’s gross profit as reported stood at $63.47 million against revenue of $32.17 million.
For the quarterly period ending June 29 this year, Xenon Pharmaceuticals Inc.’s cash and short-term investments amounted to $177.59 million against total debt of $3.5 million. Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected XENE to announce -$0.48 per share in earnings in its latest quarter, but it posted -$0.51, representing a -6.30% surprise. EBITDA for the quarter stood at more than -$22.27 million. XENE stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 17.73 million, with total debt at $3.5 million. Shareholders hold equity totaling $41.12 million
Let’s look briefly at Xenon Pharmaceuticals Inc. (XENE) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 77.34% to suggest the stock is trending Overbought, with historical volatility in this time period at 343.84%.
The stock’s 5-day moving average is $32.03, reflecting a +6.57% or $1.97 change from its current price. XENE is currently trading +81.69% above its 20-day SMA, +78.65% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +81.80% and +109.30% respectively.
Stochastic %K and %D was 91.78% and 91.70% and the average true range (ATR) pointed at 2.75. The RSI (14) points at 75.41%, while the 14-day stochastic is at 90.77% with the period’s ATR at 2.36. The stock’s 9-day MACD Oscillator is pointing at 4.09 and 8.62 on the 14-day charts.
In the most recent analyst report for Xenon Pharmaceuticals Inc. (NASDAQ: XENE), SVB Leerink launched coverage with an Outperform rating. Analysts offering their rating for XENE stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate XENE as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 9 have offered a “buy” rating.
What is XENE’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $34.00 and a high of $50.00, with their median price target at $46.00. Looking at these predictions, the average price target given by analysts is for Xenon Pharmaceuticals Inc. (XENE) stock is $45.56.